Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma

Journal of Nuclear Medicine

Volumn 40, Issue 11, 1999, Pages 1784-1791

  Delbeke, Dominique ^a   Rose, D Michael ^b   Chapman, William C ^b   Pinson, C Wright ^b   Wright, J Kelly ^b   Beauchamp, R Daniel ^b   Shyr, Yu ^b   Leach, Steven D ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Fluorodeoxyglucose; Neoplasms; Pancreas; PET

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0032744477     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin North Am. 1998;7:67-91.
2. Campbell JP, Wilson SR. Pancreatic neoplasms: how useful is evaluation with US? Radiology. 1988;167:341-344.
3. Diehl SJ, Lehman KJ, Sadick M, Lachman R, Georgi, M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology. 1998;206:373-378.
4. Lu DSK, Reber HA, Krasny RM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR. 1997;168:1439-1444.
5. Wanebo HJ, Vezeridis MP. Pancreatic carcinoma in perspective: a continuing challenge. Cancer. 1996;78:580-591.
6. Brandt KR, Charbrideau JW, Stephens DH, Welch TJ, Goellner JR. CT and US guided biopsy of the pancreas. Radiology. 1993;187:99-104.
7. Hoh CK, Schiepers C, Seltzer MA, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med. 1997;27:94-106.
8. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
9. Monakhov NK, Neistadt EL, Shavlovskil MM, et al. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27-34.
10. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased F-18 FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
11. Reske S, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased F-18 FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
12. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994;192:79-86.
13. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. F-(fluorine-18) fluoro-2-deoxy-d-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology. 1995;195:339-344.
14. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18-fluorodeoxyglucose: comparison with CT and US. Radiology. 1995;195:345-352.
15. Ho CL, Dehdashti F, Griffeth LK, et al. F-18 FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr. 1996;20:363-369.
16. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995;36:771-777.
17. Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med. 1997;24:678-682.
18. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995;196:167-173.
19. Wahl RL, Henry CA, Ethrer SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
20. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
21. Langen KJ, Braun U, Kops ER, et al. The influence of serum glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993;34:355-359.
22. Delbeke D, Patton JA, Martin WH, Sandler MP. FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders. J Nucl Med. 1999;40:110-117.
23. Delbeke D, Vitola J, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
24. Lowe VL, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules (PIOPLIN). J Clin Oncol. 1998;16:1075-1084.
25. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulocytes studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
26. 18F]-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Tomogr. 1989; 13:829-831.
27. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with F-18 FDG-PET and correlation with histopathological findings. Radiology. 1998;206;749-754.
28. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.
29. Zimny M, Buell U, Diedrichs CG, Reske SN. False-positive FDG-PET in patients with pancreatic masses: an issue of proper patient selection? Eur J Nucl Med. 1998;25:1352.
30. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: effect of object size. J Comput Assist Tomogr. 1979;3:299-308.
31. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033.
32. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage metastatic colorectal carcinoma to the liver: comparison with computed tomography (CT) and CT portography. Am J Surg. 1996;171:21-26.
33. Flanagan FN, Dehdashti F, Ogunbiyi OA, et al. The role of F-18 FDG-PET in advanced primary and recurrent colorectal cancer (abstract). J Nucl Med. 1996;31:132P.
34. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
35. Scott AM, Akhurst T, Berlangieri SU, et al. Comparison of F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography in the detection of recurrent colorectal carcinoma [abstract]. J Nucl Med. 1996;37: 132P.
36. 18F]fluorodeoxyglucose in recurrent colorectal carcinoma. Br J Surg. 1994;81:1666-1670.
37. Schiepers C, Pennincks F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517-522.
38. 18F]fluorodeoxyglucose in identifying operable colorectal cancer. Arch Surg. 1996;131:703-707.